Free tool
FAERS Monitor: Revtorpyk
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219908 or its brand name (Revtorpyk, Gedatolisib). Reports on generic versions are filed under their own applications.
Reports
20
Serious
18
90% of reports
Hospitalization
9
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hyperglycaemia7
- anaemia5
- drug ineffective4
- escherichia bacteraemia4
- leukopenia4
- pyrexia4
- pulmonary embolism2
- cellulitis1
- colitis1
- embolism1
- hyperbilirubinaemia1
- mania1
- muscular weakness1
- myocarditis1
- nausea1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 5 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,139 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| escherichia bacteraemiaSignal | 4 | 1792.6 | 745.4 | 5,474 |
| hyperglycaemiaSignal | 7 | 202.1 | 111.2 | 1,209 |
| embolism | 1 | 126.6 | 18.7 | 31 |
| hyperbilirubinaemia | 1 | 101.5 | 15.0 | 24 |
| myocarditis | 1 | 91.8 | 13.6 | 22 |
| leukopeniaSignal | 4 | 84.1 | 35.0 | 251 |
| mania | 1 | 63.9 | 9.5 | 15 |
| colitis | 1 | 27.7 | 4.1 | 6 |
| anaemiaSignal | 5 | 27.6 | 12.9 | 104 |
| pulmonary embolism | 2 | 22.1 | 5.9 | 22 |
| cellulitis | 1 | 20.9 | 3.1 | 4 |
| pyrexiaSignal | 4 | 12.2 | 5.1 | 31 |
| muscular weakness | 1 | 9.3 | 1.4 | 1 |
| drug ineffectiveSignal | 4 | 3.2 | 1.3 | 4 |
| nausea | 1 | 1.3 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.